253 related articles for article (PubMed ID: 26823889)
1. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
Liu Q; Kan Y; Zhao Y; He H; Kong L
Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889
[TBL] [Abstract][Full Text] [Related]
2. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literature.
Fu X; Jiang J; Tian XY; Li Z
Diagn Pathol; 2015 Jul; 10():106. PubMed ID: 26178751
[TBL] [Abstract][Full Text] [Related]
4. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
5. Epithelioid inflammatory myofibroblastic sarcoma in abdominal cavity: a case report and review of literature.
Wu H; Meng YH; Lu P; Ning HY; Hong L; Kang XL; Duan MG
Int J Clin Exp Pathol; 2015; 8(4):4213-9. PubMed ID: 26097614
[TBL] [Abstract][Full Text] [Related]
6. Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature.
Yu L; Liu J; Lao IW; Luo Z; Wang J
Diagn Pathol; 2016 Jul; 11(1):67. PubMed ID: 27460384
[TBL] [Abstract][Full Text] [Related]
7. Epithelioid inflammatory myofibroblastic sarcoma with recurrence after extensive resection: significant clinicopathologic characteristics of a rare aggressive soft tissue neoplasm.
Zhou J; Jiang G; Zhang D; Zhang L; Xu J; Li S; Li W; Ma Y; Zhao A; Zhao Z
Int J Clin Exp Pathol; 2015; 8(5):5803-7. PubMed ID: 26191301
[TBL] [Abstract][Full Text] [Related]
8. Cytopathologic features of epithelioid inflammatory myofibroblastic sarcoma with correlation of histopathology, immunohistochemistry, and molecular cytogenetic analysis.
Lee JC; Wu JM; Liau JY; Huang HY; Lo CY; Jan IS; Hornick JL; Qian X
Cancer Cytopathol; 2015 Aug; 123(8):495-504. PubMed ID: 26139079
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.
Rafee S; Elamin YY; Joyce E; Toner M; Flavin R; McDermott R; Sheehy N; Hennessy B; O'Byrne K; Gleeson N; Osman N
Tumori; 2015 Apr; 101(2):e35-9. PubMed ID: 25744866
[TBL] [Abstract][Full Text] [Related]
10. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
[TBL] [Abstract][Full Text] [Related]
11. Epithelioid inflammatory myofibroblastic sarcoma arising in the pleural cavity.
Kozu Y; Isaka M; Ohde Y; Takeuchi K; Nakajima T
Gen Thorac Cardiovasc Surg; 2014 Mar; 62(3):191-4. PubMed ID: 23345154
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
Yuan C; Ma MJ; Parker JV; Mekhail TM
Am J Case Rep; 2017 Jul; 18():799-804. PubMed ID: 28713152
[TBL] [Abstract][Full Text] [Related]
14. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
15. Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib.
Li M; Xing R; Huang J; Shi C; Wei C; Wang H
Front Oncol; 2023; 13():1084456. PubMed ID: 37035183
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
Gambacorti Passerini C; Farina F; Stasia A; Redaelli S; Ceccon M; Mologni L; Messa C; Guerra L; Giudici G; Sala E; Mussolin L; Deeren D; King MH; Steurer M; Ordemann R; Cohen AM; Grube M; Bernard L; Chiriano G; Antolini L; Piazza R
J Natl Cancer Inst; 2014 Feb; 106(2):djt378. PubMed ID: 24491302
[TBL] [Abstract][Full Text] [Related]
17. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.
Godbert Y; Henriques de Figueiredo B; Bonichon F; Chibon F; Hostein I; Pérot G; Dupin C; Daubech A; Belleannée G; Gros A; Italiano A; Soubeyran I
J Clin Oncol; 2015 Jul; 33(20):e84-7. PubMed ID: 24687827
[No Abstract] [Full Text] [Related]
18. Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma.
Jiang Q; Tong HX; Hou YY; Zhang Y; Li JL; Zhou YH; Xu J; Wang JY; Lu WQ
Orphanet J Rare Dis; 2017 May; 12(1):97. PubMed ID: 28535796
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7.
Takeoka K; Okumura A; Maesako Y; Akasaka T; Ohno H
Cancer Genet; 2015 Mar; 208(3):85-90. PubMed ID: 25766836
[TBL] [Abstract][Full Text] [Related]
20. Epithelioid inflammatory myofibroblastic sarcoma responsive to surgery and an ALK inhibitor in a patient with panhypopituitarism.
Kurihara-Hosokawa K; Kawasaki I; Tamai A; Yoshida Y; Yakushiji Y; Ueno H; Fukumoto M; Fukushima H; Inoue T; Hosoi M
Intern Med; 2014; 53(19):2211-4. PubMed ID: 25274232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
